Chemotherapy for small-cell lung cancer with paraneoplastic nephrotic syndrome

Radiology and Oncology

Volumn 38, Issue 2, 2004, Pages 153-154

  Kagohashi, Katsunori ^a   Ohara, Gen ^a   Satoh, Hiroaki ^a   Sekizawa, Kiyohisa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PLATINUM DERIVATIVE; VINCRISTINE;

AGED; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; GERIATRIC PATIENT; HUMAN; KIDNEY FUNCTION; LETTER; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; NEPHROTIC SYNDROME; PARANEOPLASTIC SYNDROME; TREATMENT INDICATION;

EID: 3142668981     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Metz-Kurschel U, Kurschel E, Niederle N, Aulbert E. Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin. J Cancer Res Clin Oncol 1990; 116: 203-6.
2. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
3. Livingston RB. Combined modality therapy of lung cancer. Clin Cancer Res 1997; 3: 2638-1647.
4. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(Suppl 1): 3-13.
5. Jermanovich NB, Giammarco R, Ginsberg SJ, Tinsley RW, Jones DB. Small cell anaplastic carcinoma of the lung with mesangial proliferative glomerulonephritis. Arch Intern Med 1982; 142: 397-9.
6. Boon ES, Vrij AA, Nieuwhof C, van Noord JA, Zeppenfeldt E. Small cell lung cancer with paraneoplastic nephrotic syndrome. Eur Respir J 1994; 7: 1192-3.
7. Tomoda K, Hamada K, Fukuoka K, Tsukaguchi K, Tsujimoto M, Mikasa K, et al. [Small cell lung cancer associated with nephrotic syndrome; remission after chemotherapy.] [Japanese with English abstract]. Nihon Kokyuki Gakkai Zasshi 1998; 36: 541-4.